Escobar, C.; Pascual-Figal, D.; Manzano, L.; Nuñez, J.; Camafort, M.
Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin. J. Clin. Med. 2023, 12, 6798.
https://doi.org/10.3390/jcm12216798
AMA Style
Escobar C, Pascual-Figal D, Manzano L, Nuñez J, Camafort M.
Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin. Journal of Clinical Medicine. 2023; 12(21):6798.
https://doi.org/10.3390/jcm12216798
Chicago/Turabian Style
Escobar, Carlos, Domingo Pascual-Figal, Luis Manzano, Julio Nuñez, and Miguel Camafort.
2023. "Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin" Journal of Clinical Medicine 12, no. 21: 6798.
https://doi.org/10.3390/jcm12216798
APA Style
Escobar, C., Pascual-Figal, D., Manzano, L., Nuñez, J., & Camafort, M.
(2023). Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin. Journal of Clinical Medicine, 12(21), 6798.
https://doi.org/10.3390/jcm12216798